Although we only recruited two patients with BRAFV600E mutations, a high response rate of 50% was observed, which was in line with genomic determinants of response to PD-1 blockade, including an enrichment of mitogen-activated protein kinase (MAPK) pathway alterations (BRAF) in responders36 and higher frequencies of tumor-associated lymphocytes associated with BRAF mutations.37 The gene discussed is WNK2; the disease is neoplasm.